Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Puma Biotechnology, Inc.    PBYI

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
10.9(c) 11.05(c) 11.73(c) 11.25(c) 11.97(c) Last
452 019 391 377 233 468 444 627 1 114 722 Volume
-5.30% +1.38% +6.15% -4.09% +6.40% Change
More quotes
Financials (USD)
Sales 2020 226 M - -
Net income 2020 -52,1 M - -
Net cash position 2020 45,2 M - -
P/E ratio 2020 -8,77x
Yield 2020 -
Sales 2021 249 M - -
Net income 2021 -35,7 M - -
Net cash position 2021 136 M - -
P/E ratio 2021 -12,6x
Yield 2021 -
Capitalization 476 M 476 M -
EV / Sales 2020 1,91x
EV / Sales 2021 1,37x
Nbr of Employees 269
Free-Float 86,5%
More Financials
Company
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks... 
Sector
Biotechnology & Medical Research
Calendar
12/09 | 09:00amPresentation
More about the company
Notations Surperformance© of Puma Biotechnology, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about PUMA BIOTECHNOLOGY, INC.
11/17PUMA BIOTECHNOLOGY : to Present Neratinib Data at the San Antonio Breast Cancer ..
BU
11/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)..
BU
11/05PUMA BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/05PUMA BIOTECH : 3Q Earnings Snapshot
AQ
11/05PUMA BIOTECHNOLOGY : Announces Interim Results from the Phase II SUMMIT Trial of..
BU
11/05PUMA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Other ..
AQ
11/05PUMA BIOTECHNOLOGY : Reports Third Quarter 2020 Financial Results
BU
11/03PUMA BIOTECHNOLOGY : to Present at the Credit Suisse 29th Annual Virtual Healthc..
BU
10/22PUMA BIOTECHNOLOGY : to Host Conference Call to Discuss Third Quarter Financial ..
BU
10/05PUMA BIOTECHNOLOGY : Announces Publication of Overall Survival Results from Phas..
BU
10/02PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)..
BU
09/08PUMA BIOTECHNOLOGY : to Present at the H.C. Wainwright 22nd Annual Global Invest..
BU
09/03PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)..
BU
08/19PUMA BIOTECHNOLOGY : Announces Publication of Interim Results of Phase II CONTRO..
BU
08/10PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)..
BU
More news
News in other languages on PUMA BIOTECHNOLOGY, INC.
2019PUMA BIOTECHNOLOGY : und Pierre Fabre schließen exklusiven Lizenzvertrag zur Ent..
2019PUMA BIOTECHNOLOGY : et Pierre Fabre concluent un accord de licence exclusive po..
More news
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | PBYI | US74587V1070 | MarketScreener
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 10,33 $
Last Close Price 11,97 $
Spread / Highest target 33,7%
Spread / Average Target -13,7%
Spread / Lowest Target -49,9%
EPS Revisions
Managers
NameTitle
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Richard Paul Bryce Chief Medical & Scientific Officer
Jay M. Moyes Independent Director
Troy E. Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PUMA BIOTECHNOLOGY, INC.36.80%476
MODERNA, INC.620.91%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.87.85%41 539
IQVIA HOLDINGS INC.10.82%32 829
SEAGEN INC.55.27%31 988